Posted by Michael Wonder on 02 Nov 2016
Health Canada approves Alecensaro - a targeted oral treatment - for patients with aggressive and rare form of lung cancer
31 October 2016 - Early data suggests Alencensaro also shows strong efficacy in treating the spread of lung cancer to the brain, a critical unmet need for patients
Roche Canada announced today that Health Canada has approved Alecsensaro (alectinib) as a monotherapy for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic non-small-cell lung cancer who have progressed on or are intolerant to crizotinib.
